Grupos Investigadores

Miembros del Grupo

Líneas de Investigación

  • Mecanismos moleculares en el desarrollo y progresión de la leucemia mieloide aguda.
  • Estudio de la oncoproteína SET como diana terapéutica en leucemia mieloide aguda.
  • Desarrollo de una nueva herramienta para la búsqueda de tratamientos antitumorales más eficaces empleando el modelo animal de pez cebra.
  • Desarrollo de nuevas terapias combinadas en la leucemia mieloide aguda. Hacia un tratamiento personalizado en pacientes con sobreexpresión de la oncoproteína SET.

Palabras Clave

  • SET
  • PP2A
  • Leucemia mieloide aguda

Publicaciones Científicas desde 2018

  • Autores: Pippa, R. (Autor de correspondencia); Odero, María D.
    Revista: CELLS
    ISSN 2073-4409 Vol.9 N° 3 2020 págs. 544
    The MYC transcription factor is one of the best characterized PP2A substrates. Deregulation of the MYC oncogene, along with inactivation of PP2A, are two frequent events in cancer. Both proteins are essential regulators of cell proliferation, apoptosis, and differentiation, and they, directly and indirectly, regulate each other's activity. Studies in cancer suggest that targeting the MYC/PP2A network is an achievable strategy for the clinic. Here, we focus on and discuss the role of MYC and PP2A in myeloid leukemias.
  • Autores: Arriazu Ruiz, Elena (Autor de correspondencia); Vicente Vázquez, Carmen; Pippa, R.; et al.
    ISSN 2044-5385 Vol.10 N° 1 2020
    Acute myeloid leukemia (AML) is an aggressive hematologic malignancy. Although novel emerging drugs are available, the overall prognosis remains poor and new therapeutic approaches are required. PP2A phosphatase is a key regulator of cell homeostasis and is recurrently inactivated in AML. The anticancer activity of several PP2A-activating drugs (e.g., FTY720) depends on their interaction with the SET oncoprotein, an endogenous PP2A inhibitor that is overexpressed in 30% of AML cases. Elucidation of SET regulatory mechanisms may therefore provide novel targeted therapies for SET-overexpressing AMLs. Here, we show that upregulation of protein kinase p38 beta is a common event in AML. We provide evidence that p38 beta potentiates SET-mediated PP2A inactivation by two mechanisms: facilitating SET cytoplasmic translocation through CK2 phosphorylation, and directly binding to and stabilizing the SET protein. We demonstrate the importance of this new regulatory mechanism in primary AML cells from patients and in zebrafish xenograft models. Accordingly, combination of the CK2 inhibitor CX-4945, which retains SET in the nucleus, and FTY720, which disrupts the SET-PP2A binding in the cytoplasm, significantly reduces the viability and migration of AML cells. In conclusion, we show that the p38 beta/CK2/SET axis represents a new potential therapeutic pathway in AML patients with SET-dependent PP2A inactivation.
  • Autores: Vicente Vázquez, Carmen (Autor de correspondencia); Arriazu Ruiz, Elena; Martinez-Balsalobre, E.; et al.
    ISSN 0304-3835 Vol.468 2020 págs. 1 - 13
    Acute myeloid leukemia (AML) is an aggressive disease associated with very poor prognosis. Most patients are older than 60 years, and in this group only 5-15% of cases survive over 5 years. Therefore, it is urgent to develop more effective targeted therapies. Inactivation of protein phosphatase 2 A (PP2A) is a recurrent event in AML, and overexpression of its endogenous inhibitor SET is detected in similar to 30% of patients. The PP2A activating drug FTY720 has potent anti-leukemic effects; nevertheless, FTY720 induces cardiotoxicity at the anti-neoplastic dose. Here, we have developed a series of non-phosphorylable FTY720 analogues as a new therapeutic strategy for AML. Our results show that the lead compound CM-1231 re-activates PP2A by targeting SET-PP2A interaction, inhibiting cell proliferation and promoting apoptosis in AML cell lines and primary patient samples. Notably, CM-1231 did not induce cardiac toxicity, unlike FTY720, in zebrafish models, and reduced the invasion and aggressiveness of AML cells more than FTY720 in zebrafish xenograft models. In conclusion, CM-1231 is safer and more effective than FTY720; therefore, this compound could represent a novel and promising approach for treating AML patients with SET overexpression.
  • Autores: Pippa, R. (Autor de correspondencia); Boffo, S.; Odero, María D.; et al.
    ISSN 0021-9541 Vol.235 N° 6 2020 págs. 5284 - 5292
    Mesothelioma is an aggressive tumor that affects thousands of people every year. The therapeutic options for patients are limited; hence, a better understanding of mesothelioma biology is crucial to improve patient survival. To find new molecular targets and therapeutic strategies related to the protein phosphatase 2A (PP2A) network, we analyzed the gene expression of known PP2A inhibitors in mesothelioma patient samples. Our analysis disclosed a general overexpression of all PP2A-negative regulators in mesothelioma patients. Moreover, the expression of ANP32E and CIP2A genes, increased in 16% and 11% of cases, positively correlates with the ones of all the other PP2A regulators and the ones of the main cyclins and CDKs, suggesting the existence of a feed-forward loop that might contribute to the mesothelioma progression via PP2A inactivation. Overall, our study indicates the existence of a strategic and targetable axis between PP2A inhibitors (ANP32E and CIP2A) and cell cycle regulators (cyclin B2/CDK1) and provides a valuable rationale for using a personalized combinational therapy approach to improve mesothelioma patient survival.
  • Autores: Cendon-Florez, Y. ; Pippa, R. ; Boffo, S.; et al.
    ISSN 0008-5472 Vol.80 N° 16 2020
  • Autores: Perrotti, D. (Autor de correspondencia); Agarwal, A.; Lucas, C. M. ; et al.
    ISSN 1946-6234 Vol.11 N° 501 2019 págs. eaau0416
  • Autores: Broux, M. ; Prieto, C.; Demeyer, S.; et al.
    Revista: BLOOD
    ISSN 0006-4971 Vol.134 N° 16 2019 págs. 1323 - 1336
    The polycomb repressive complex 2, with core components EZH2, SUZ12, and EED, is responsible for writing histone 3 lysine 27 trimethylation histone marks associated with gene repression. Analysis of sequence data from 419 T-cell acute lymphoblastic leukemia (T-ALL) cases demonstrated a significant association between SUZ12 and JAK3 mutations. Here we show that CRISPR/Cas9-mediated inactivation of Suz12 cooperates with mutant JAK3 to drive T-cell transformation and T-ALL development. Gene expression profiling integrated with ChIP-seq and ATAC-seq data established that inactivation of Suz12 led to increased PI3K/mammalian target of rapamycin (mTOR), vascular endothelial growth factor (VEGF), and WNT signaling. Moreover, a drug screen revealed that JAK3/Suz12 mutant leukemia cells were more sensitive to histone deacetylase (HDAC)6 inhibition than JAK3 mutant leukemia cells. Among the broad genome and gene expression changes observed on Suz12 inactivation, our integrated analysis identified the PI3K/mTOR, VEGF/VEGF receptor, and HDAC6/HSP90 pathways as specific vulnerabilities in T-ALL cells with combined JAK3 and SUZ12 mutations.
  • Autores: Macias, R. I. R. (Autor de correspondencia); Sánchez-Martín, A.; Rodríguez-Macías, G.; et al.
    Revista: ONCOTARGET
    ISSN 1949-2553 2018

Proyectos desde 2018

  • Título: Mecanismos y eficacia de terapias combinadas basadas en la activación funcional de PP2A en leucemia mieloide aguda. Papel de las subunidades reguladoras PP2A como dianas terapéuticas.
    Código de expediente: PI20/01558
    Investigador principal: MARIA DOLORES ODERO DE DIOS.
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 268.620,00 €
    Fondos FEDER: SI
  • Título: Xenoinjertos derivados de paciente en pez cebra: una nueva plataforma para la investigación traslacional en leucemia mieloide aguda
    Código de expediente: PI020 PDX-AML
    Investigador principal: MARIA DOLORES ODERO DE DIOS.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2019 GN Centros
    Fecha de inicio: 07-09-2019
    Fecha fin: 30-11-2019
    Importe concedido: 59.184,43 €
    Fondos FEDER: NO
  • Título: Desarrollo de nuevas terapias combinadas en la leucemia mieloide aguda. Hacia un tratamiento personalizado en pacientes con sobreexpresión de la oncoproteina SET
    Código de expediente: PI17/02272
    Investigador principal: MARIA DOLORES ODERO DE DIOS.
    Fecha de inicio: 01-01-2018
    Fecha fin: 31-12-2020
    Importe concedido: 147.620,00 €
    Fondos FEDER: SI
  • Título: Estudio de la oncoproteína SET como diana terapéutica en leucemia mieloide aguda. Hacia un tratamiento personalizado mediante la combinación de activadores de la PP2A e inhibidores tirosinasa quinasas en pacientes con sobreexpresión de SET
    Código de expediente: 29/2015
    Investigador principal: MARIA DOLORES ODERO DE DIOS.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2015 GN SALUD
    Fecha de inicio: 06-12-2015
    Fecha fin: 05-12-2018
    Importe concedido: 47.510,00 €
    Fondos FEDER: NO
  • Título: Ayuda a Investigadores 2017 AECC
    Investigador principal: MARIA DOLORES ODERO DE DIOS
    Convocatoria: Investigador AECC 2018
    Fecha de inicio: 01-10-2018
    Fecha fin: 31-12-2022
    Importe concedido: 212.500,00 €